CY1106594T1 - Αντισωματα εναντι ανθρωπινης il-12 - Google Patents

Αντισωματα εναντι ανθρωπινης il-12

Info

Publication number
CY1106594T1
CY1106594T1 CY20071100657T CY071100657T CY1106594T1 CY 1106594 T1 CY1106594 T1 CY 1106594T1 CY 20071100657 T CY20071100657 T CY 20071100657T CY 071100657 T CY071100657 T CY 071100657T CY 1106594 T1 CY1106594 T1 CY 1106594T1
Authority
CY
Cyprus
Prior art keywords
human
antibodies
bioactivity
heterodimer
potency
Prior art date
Application number
CY20071100657T
Other languages
Greek (el)
English (en)
Inventor
Maurcie Kent Gately
David Howard Presky
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22106938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1106594T1 publication Critical patent/CY1106594T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20071100657T 1998-01-23 2007-05-15 Αντισωματα εναντι ανθρωπινης il-12 CY1106594T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7233398P 1998-01-23 1998-01-23
PCT/EP1999/000202 WO1999037682A2 (en) 1998-01-23 1999-01-15 Antibodies against human il-12

Publications (1)

Publication Number Publication Date
CY1106594T1 true CY1106594T1 (el) 2012-01-25

Family

ID=22106938

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100657T CY1106594T1 (el) 1998-01-23 2007-05-15 Αντισωματα εναντι ανθρωπινης il-12
CY20121100589T CY1112927T1 (el) 1998-01-23 2012-06-29 Αντισωματα κατα της ανθρωπινης il-12

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100589T CY1112927T1 (el) 1998-01-23 2012-06-29 Αντισωματα κατα της ανθρωπινης il-12

Country Status (18)

Country Link
US (1) US6225117B1 (cg-RX-API-DMAC10.html)
EP (2) EP1049717B1 (cg-RX-API-DMAC10.html)
JP (3) JP4481489B2 (cg-RX-API-DMAC10.html)
KR (1) KR100764256B1 (cg-RX-API-DMAC10.html)
CN (2) CN101274962A (cg-RX-API-DMAC10.html)
AR (2) AR014459A1 (cg-RX-API-DMAC10.html)
AT (2) ATE553129T1 (cg-RX-API-DMAC10.html)
AU (1) AU759624B2 (cg-RX-API-DMAC10.html)
BR (1) BR9907743A (cg-RX-API-DMAC10.html)
CA (1) CA2318052C (cg-RX-API-DMAC10.html)
CY (2) CY1106594T1 (cg-RX-API-DMAC10.html)
DE (1) DE69935574T2 (cg-RX-API-DMAC10.html)
DK (2) DK1049717T3 (cg-RX-API-DMAC10.html)
ES (2) ES2284242T3 (cg-RX-API-DMAC10.html)
PT (2) PT1049717E (cg-RX-API-DMAC10.html)
TR (1) TR200002145T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999037682A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA99452B (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399379B1 (en) 1992-09-29 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p35 subunit expression
WO2003104495A1 (en) * 2002-06-11 2003-12-18 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6448081B1 (en) 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
DK1137766T3 (da) * 1998-12-09 2006-01-30 Protein Design Labs Inc Anvendelse af IL-12-antistoffer til behandling af psoriasis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
EP1259544B1 (en) * 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
EP1711527A4 (en) * 2003-12-15 2008-09-03 Dendreon Corp HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2591813A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
CN103145837A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5809360A (en) * 1996-08-07 1998-09-15 Agfa Division - Bayer Corporation Cassette for storing and accessing plates within an automated plate handler
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies

Also Published As

Publication number Publication date
CN100374466C (zh) 2008-03-12
AR014459A1 (es) 2001-02-28
EP1049717A2 (en) 2000-11-08
JP4481489B2 (ja) 2010-06-16
CN101274962A (zh) 2008-10-01
JP2002501085A (ja) 2002-01-15
DE69935574D1 (de) 2007-05-03
KR100764256B1 (ko) 2007-10-05
ATE357459T1 (de) 2007-04-15
CN1288468A (zh) 2001-03-21
JP2013139458A (ja) 2013-07-18
US6225117B1 (en) 2001-05-01
WO1999037682A3 (en) 1999-11-18
DE69935574T2 (de) 2007-12-06
EP1818343A3 (en) 2007-08-22
EP1818343A2 (en) 2007-08-15
CA2318052A1 (en) 1999-07-29
JP2009197008A (ja) 2009-09-03
TR200002145T2 (tr) 2000-11-21
ES2284242T3 (es) 2007-11-01
DK1818343T3 (da) 2012-07-16
EP1049717B1 (en) 2007-03-21
ES2386262T3 (es) 2012-08-14
EP1818343B1 (en) 2012-04-11
KR20010034315A (ko) 2001-04-25
ZA99452B (en) 1999-07-23
CY1112927T1 (el) 2016-04-13
BR9907743A (pt) 2000-10-17
PT1818343E (pt) 2012-07-12
WO1999037682A2 (en) 1999-07-29
PT1049717E (pt) 2007-05-31
AU2517799A (en) 1999-08-09
CA2318052C (en) 2012-07-03
ATE553129T1 (de) 2012-04-15
DK1049717T3 (da) 2007-07-30
AU759624B2 (en) 2003-04-17
AR061801A2 (es) 2008-09-24

Similar Documents

Publication Publication Date Title
WO1999037682A3 (en) Antibodies against human il-12
NO20055773D0 (no) Immunoglobin kimeriske monomere-dimere hybrider
CO4480033A1 (es) Proteina accesoria humana para receptores de la interleucina 1
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
NZ568769A (en) Human monoclonal antibodies against CD20
DK0616537T3 (da) CDw52-specifikt antistof til behandling af dissemineret sclerose
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EA202192294A1 (ru) Антитела к trem2 и способы их применения
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
ATE439166T1 (de) Hemmung von il-17 produktion
EA200300663A1 (ru) Антагонисты cxcr3
DK0973550T3 (da) Antagonistiske anti-AVB3-integrin-antistoffer
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
CY1107858T1 (el) Ccr5 αντισωματα pa14
ATE547525T1 (de) Lösliche zcyctor 11 cytokinrezeptoren
DE69529822D1 (de) Interleukin-15-rezeptoren
ITTO20020340A1 (it) Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
AR047819A1 (es) Un anticuerpo monoclonal anti-tenascina humana
CY1105629T1 (el) Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv
ATE132502T1 (de) Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung
ES2116906B1 (es) Anticuerpo monocional pc2.27 asociado a tumores.